Pfizer’s Inclacumab Study: A Step Forward in Sickle Cell Disease Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.

Pfizer Inc. is conducting an open-label extension study titled ‘An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial.’ The study aims to assess the long-term safety of inclacumab, a drug administered to individuals with sickle cell disease (SCD) who have previously participated in an inclacumab clinical trial. This research is significant as it seeks to ensure the ongoing safety of a treatment that could potentially improve the quality of life for those with SCD.

The intervention being tested is inclacumab, an experimental drug administered intravenously at a dose of 30 mg/kg every 12 weeks. Inclacumab is intended to provide therapeutic benefits to individuals suffering from sickle cell disease.

The study is designed as an interventional, single-group assignment with no masking, focusing primarily on treatment. This means all participants receive the same treatment, and both researchers and participants are aware of the intervention being administered.

The study began on March 29, 2022, and is actively not recruiting new participants. The primary completion date is yet to be determined, with the last update submitted on June 24, 2025. These dates are crucial for tracking the progress and timeline of the study.

The market implications of this study are significant for Pfizer, as positive results could enhance investor confidence and potentially boost the company’s stock performance. The study’s outcome may also influence the competitive landscape in the pharmaceutical industry, particularly in the treatment of sickle cell disease.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.